World Journal of Urology

, Volume 23, Issue 6, pp 374–384

Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction

  • Alberto Briganti
  • Andrea Salonia
  • Federico Deho’
  • Giuseppe Zanni
  • Luigi Barbieri
  • Patrizio Rigatti
  • Francesco Montorsi
Topic Paper

DOI: 10.1007/s00345-005-0022-6

Cite this article as:
Briganti, A., Salonia, A., Deho’, F. et al. World J Urol (2005) 23: 374. doi:10.1007/s00345-005-0022-6

Abstract

Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of which three are available. Sildenafil is the most widely prescribed oral agent for ED and has a very satisfactory efficacy–safety profile in all patient categories. Tadalafil and vardenafil were introduced in the European Union and in the United States in 2003 and 2004, respectively. The three PDE-5 inhibitors share many pharmacological and clinical characteristics, and each has unique features. This review, which is based on the contemporary literature on PDE-5 inhibitors, describes the chemical, pharmacological, and clinical features of sildenafil, vardenafil, and tadalafil. The first section reviews the pathophysiology of penile erection and PDE-5 inhibitor pharmacology. The second section summarizes data regarding efficacy and safety of the three drugs in treating ED in the general population as well as in selected patient categories.

Keywords

Erectile dysfunctionPhosphodiesterase type-5 inhibitorsSildenafilTadalafilVardenafil

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Alberto Briganti
    • 1
  • Andrea Salonia
    • 1
  • Federico Deho’
    • 1
  • Giuseppe Zanni
    • 1
  • Luigi Barbieri
    • 1
  • Patrizio Rigatti
    • 1
  • Francesco Montorsi
    • 1
    • 2
  1. 1.Department of UrologyUniversitá Vita-Salute San RaffaeleMilanItaly
  2. 2.Cattedra di UrologiaUniversitá Vita-Salute San RaffaeleMilanItaly